Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Earnings Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. Cyclacel Pharmaceuticals had a negative net margin of 1,128.13% and a negative return on equity of 72.48%.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) traded down 2.96% during mid-day trading on Thursday, hitting $1.64. 490,428 shares of the stock were exchanged. The company has a 50-day moving average price of $2.74 and a 200-day moving average price of $4.25. Cyclacel Pharmaceuticals has a one year low of $1.56 and a one year high of $10.90.
ILLEGAL ACTIVITY WARNING: “Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Earnings Results” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/cyclacel-pharmaceuticals-inc-cycc-posts-earnings-results/1470989.html.
In other Cyclacel Pharmaceuticals news, major shareholder Eastern Capital Ltd purchased 850,000 shares of the business’s stock in a transaction dated Wednesday, July 19th. The stock was bought at an average cost of $2.00 per share, for a total transaction of $1,700,000.00. Following the completion of the acquisition, the insider now directly owns 2,167,261 shares in the company, valued at $4,334,522. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.00% of the stock is owned by insiders.
Separately, Zacks Investment Research downgraded shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 26th.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.